Early double stent thrombosis associated with clopidogrel hyporesponsivenesss

Netherlands Heart Journal

Volumn 20, Issue 1, 2012, Pages 38-41

  Rademakers, L M ^a   Dewilde, W ^a   Van de Kerkhof, D ^a  

^a CATHARINA HOSPITAL   (Netherlands)

Author keywords

Thrombosis. stents. clopidogrel. prasugrel. CYP2C19

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; HEPARIN; HIRUDIN; PRASUGREL; PROSTAGLANDIN E1;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; AORTA BALLOON; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; CORONARY CARE UNIT; CYP2C19 GENE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG IMPLANTATION; DRUG RESPONSE; DRUG SUBSTITUTION; EMERGENCY TREATMENT; FOLLOW UP; GENE PRODUCT; GENETIC VARIABILITY; HEART HEMODYNAMICS; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; ST SEGMENT ELEVATION; STENT THROMBOSIS; THORAX PAIN; THROMBOCYTE AGGREGATION;

EID: 84856253102     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-011-0165-6     Document Type: Article

References (17)

1. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;1:216-35.
2. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;24:2312-7.
3. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;20:2420-5.
4. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;17:2344-51.
5. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost. 2008;1:121-6.
6. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;15:1967-71.
7. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;2:246-51.
8. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;23:2908-13.
9. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;5:891-6.
10. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;4:363-75.
11. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;4:354-62.
12. De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost. 2008;2:196-203.
13. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;9660:309-17.
14. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;20:2001-15.
15. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidog-rel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol. 2009;1:5-10.
16. Mehta SR. CURRENT OASIS-7: benefit to doubling clopidogrel dose in ACS patients undergoing PCI. Presented at: European Society of Cardiology 2009 Congress; August 30, 2009; Barcelona, Spain. 2009.
17. Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J. 2009;5:818-24. 824 e811.